CA2765394A1 - Variants de la sap et leur utilisation - Google Patents
Variants de la sap et leur utilisation Download PDFInfo
- Publication number
- CA2765394A1 CA2765394A1 CA2765394A CA2765394A CA2765394A1 CA 2765394 A1 CA2765394 A1 CA 2765394A1 CA 2765394 A CA2765394 A CA 2765394A CA 2765394 A CA2765394 A CA 2765394A CA 2765394 A1 CA2765394 A1 CA 2765394A1
- Authority
- CA
- Canada
- Prior art keywords
- sap
- variant
- seq
- amino acid
- oligomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Les polypeptides sont sensibles à une dénaturation ou à une dégradation enzymatique dans le sang, le foie ou le rein. A cause de la faible stabilité de certains polypeptides, il a été nécessaire d'administrer des médicaments polypeptidiques à une fréquence soutenue à un sujet afin de maintenir une concentration plasmatique efficace de la substance active. En outre, les compositions pharmaceutiques des peptides thérapeutiques présentent de préférence une durée de conservation de plusieurs années afin d'être appropriées pour une utilisation courante. Toutefois, les compositions peptidiques sont instables de manière intrinsèque à cause d'une sensibilité envers une dégradation chimique et physique. En partie, l'invention concerne des protéines variantes de la SAP, des compositions, des préparations et des formulations pharmaceutiques présentant une prolongation de la demi-vie in vivo, une prolongation de la durée de conservation ou une stabilité in vitro plutôt augmentée ou une efficacité de production accrue comparativement à la SAP humaine. Les avantages d'une augmentation de la demi-vie plasmatique comprennent, sans limitation, une réduction de la quantité et/ou de la fréquence d'administration des doses.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3083911A CA3083911C (fr) | 2009-06-17 | 2010-06-17 | Variants de la sap et leur utilisation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26896109P | 2009-06-17 | 2009-06-17 | |
US61/268,961 | 2009-06-17 | ||
PCT/US2010/039043 WO2010148234A1 (fr) | 2009-06-17 | 2010-06-17 | Variants de la sap et leur utilisation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3083911A Division CA3083911C (fr) | 2009-06-17 | 2010-06-17 | Variants de la sap et leur utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2765394A1 true CA2765394A1 (fr) | 2010-12-23 |
CA2765394C CA2765394C (fr) | 2020-08-18 |
Family
ID=43354870
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2765394A Active CA2765394C (fr) | 2009-06-17 | 2010-06-17 | Variants de la sap et leur utilisation |
CA3083911A Active CA3083911C (fr) | 2009-06-17 | 2010-06-17 | Variants de la sap et leur utilisation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3083911A Active CA3083911C (fr) | 2009-06-17 | 2010-06-17 | Variants de la sap et leur utilisation |
Country Status (11)
Country | Link |
---|---|
US (2) | US8329659B2 (fr) |
EP (2) | EP2987803B1 (fr) |
JP (2) | JP5822826B2 (fr) |
AU (1) | AU2010262847B2 (fr) |
CA (2) | CA2765394C (fr) |
DK (2) | DK2987803T3 (fr) |
ES (2) | ES2708823T3 (fr) |
HK (2) | HK1169997A1 (fr) |
HU (2) | HUE041034T2 (fr) |
PL (1) | PL2987803T3 (fr) |
WO (1) | WO2010148234A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108114001B (zh) * | 2017-12-23 | 2023-05-30 | 中国科学院海洋研究所 | 一种诱导海产双壳贝类产卵的诱导剂及其应用方法 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9884899B2 (en) * | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
ES2612922T3 (es) * | 2009-03-11 | 2017-05-19 | Promedior Inc. | Métodos de tratamiento y diagnóstico para trastornos de hipersensibilidad |
PT2405929T (pt) * | 2009-03-11 | 2018-07-23 | Promedior Inc | Métodos de tratamento para distúrbios autoimunes |
UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
EP2987803B1 (fr) * | 2009-06-17 | 2018-08-29 | Promedior Inc. | Variantes de sap et leurs utilisations |
WO2013090524A1 (fr) * | 2011-12-14 | 2013-06-20 | The Texas A&M University System | Procédés de gestion du déplacement des neutrophiles à l'aide de l'amyloïde p sérique (sap) et compositions associées |
WO2013096847A1 (fr) | 2011-12-21 | 2013-06-27 | Promedior, Inc. | Protéines de fusion de p-anticorps sérum amyloïde |
CN114053395A (zh) | 2013-10-08 | 2022-02-18 | 普罗麦迪奥股份有限公司 | 用于治疗纤维化癌症的方法 |
RU2017139122A (ru) * | 2015-04-15 | 2019-05-15 | Промедиор, Инк. | Способы лечения миелопролиферативных нарушений |
EP3669885A1 (fr) * | 2018-12-20 | 2020-06-24 | Humanitas Mirasole S.p.A. | Utilisation de sap pour le traitement d'infections par des champignons eurotiomycetes |
IL302388A (en) * | 2020-11-02 | 2023-06-01 | Attralus Inc | SAP FC fusion proteins and methods of use |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023A (en) * | 1847-03-20 | Stocking-loom | ||
GB1562244A (en) * | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
GB1594389A (en) | 1977-06-03 | 1981-07-30 | Max Planck Gesellschaft | Dressing material for wounds |
GB8516081D0 (en) * | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
US6071517A (en) * | 1986-07-07 | 2000-06-06 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
DE3853219T2 (de) * | 1987-11-20 | 1995-06-29 | Kanegafuchi Chemical Ind | Methode zur Entfernung von Serum-Amyloid-Protein. |
US7070994B2 (en) * | 1988-03-21 | 2006-07-04 | Oxford Biomedica (Uk) Ltd. | Packaging cells |
US5272258A (en) | 1989-06-29 | 1993-12-21 | Rush-Presbyterian-St. Luke's Medical Center | Monoclonal antibodies to C-reactive protein |
US5092876A (en) * | 1989-08-30 | 1992-03-03 | The United States Of America As Represented By The Department Of Health And Human Services | Cell attachment peptides derived from amyloid P component |
AU2158292A (en) | 1991-05-31 | 1993-01-08 | New England Deaconess Hospital Corporation | Cea-binding proteins and methods for their isolation and use |
US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
US6054121A (en) * | 1993-02-26 | 2000-04-25 | The Picower Institute For Medical Research | Modulation of immune responses in blood-borne mesenchymal cells |
US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
US5804446A (en) * | 1993-02-26 | 1998-09-08 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
AU7043694A (en) | 1993-05-27 | 1994-12-20 | Regents Of The University Of Michigan, The | Method of treatment and prevention of immune complex-induced lung injury |
US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
GB9317120D0 (en) * | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
US5981470A (en) | 1994-06-07 | 1999-11-09 | The University Of Birmingham | Uterine fibroid treatment |
US5989811A (en) * | 1994-09-29 | 1999-11-23 | Urocor, Inc. | Sextant core biopsy predictive mechanism for non-organ confined disease status |
US5750345A (en) * | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
AU712819B2 (en) | 1996-01-25 | 1999-11-18 | Profylakse Aps | Pharmaceutical composition comprising serum amyloid P component for proph ylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components |
US6365570B1 (en) * | 1997-10-10 | 2002-04-02 | Universiteit Utrecht | Pharmaceutical and diagnostic use of Serum Amyloid P component |
US20020058284A1 (en) | 1998-02-17 | 2002-05-16 | Jan G.J. Van De Winkel | Methods and compositions for treating macrophage-mediated diseases |
AU2747199A (en) | 1998-03-11 | 1999-09-27 | Kabushiki Kaisha Soken | Skin normalizing agents |
JPH11319542A (ja) | 1998-05-08 | 1999-11-24 | Tokuyama Corp | 超薄層の製造方法 |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6600019B2 (en) * | 2000-01-06 | 2003-07-29 | Curagen Corporation | Polypeptides and nucleic acids encoding same |
EP1267795A1 (fr) | 2000-03-30 | 2003-01-02 | Brennen Medical Inc. | Composition anti-microbienne et immunostimulante |
US20040068095A1 (en) * | 2001-03-14 | 2004-04-08 | Shimkets Richard A. | Novel human proteins, polynucleotides encoding them and methods of using the same |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US6872541B2 (en) * | 2001-07-25 | 2005-03-29 | Coulter International Corp. | Method and compositions for analysis of pentraxin receptors as indicators of disease |
US6537811B1 (en) * | 2001-08-01 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of SAP-1 expression |
US20030199442A1 (en) | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US7022476B2 (en) * | 2002-02-26 | 2006-04-04 | New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery | Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof |
GB0211136D0 (en) | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
ES2369216T3 (es) * | 2002-05-17 | 2011-11-28 | Novartis Pharma Ag | Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético. |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
EP1534335B9 (fr) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Anticorps specifiques du recepteur fcgammariib et procedes d'utilisation de ces anticorps |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8012472B2 (en) | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
US7763256B2 (en) * | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
EP1576368B1 (fr) | 2002-12-23 | 2009-02-18 | William Marsh Rice Univeristy | Techniques et compositions permettant de renforcer la formation de fibroblastes |
WO2004076486A1 (fr) | 2003-02-27 | 2004-09-10 | Theravision Gmbh | Methode de diminution des niveaux de proteine c-reactive |
CA2563314A1 (fr) | 2004-04-16 | 2005-12-08 | Macrogenics, Inc. | Anticorps specifiques de fcyriib et methodes d'utilisation de ces anticorps |
KR101297146B1 (ko) | 2004-05-10 | 2013-08-21 | 마크로제닉스, 인크. | 인간화 FcγRIIB 특이적 항체 및 그의 사용 방법 |
JP2008508860A (ja) | 2004-06-03 | 2008-03-27 | メダレツクス・インコーポレーテツド | Fcγ受容体1(CD64)に対するヒトモノクローナル抗体 |
WO2006002930A2 (fr) | 2004-06-30 | 2006-01-12 | Friedrich-Alexander- Universitaet Erlangen- Nuernberg | Polymorphisme fcgammariia et son utilisation dans un diagnostic |
WO2006028956A2 (fr) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Anticorps anti-recepteur fcgammariib et correspondantes |
AU2005286763A1 (en) * | 2004-09-17 | 2006-03-30 | Biomarin Pharmaceutical, Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
WO2007047796A2 (fr) | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation |
PL2029173T3 (pl) | 2006-06-26 | 2017-04-28 | Macrogenics, Inc. | Przeciwciała swoiste dla FC RIIB i sposoby ich zastosowania |
CA2708004C (fr) | 2006-12-04 | 2015-12-01 | Promedior, Inc. | Therapie conjointe pour le traitement de maladies fibrotiques |
US8497243B2 (en) * | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
US9884899B2 (en) * | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
DK2185581T3 (en) * | 2007-07-06 | 2015-12-14 | Promedior Inc | Methods and compositions suitable for treating mucositis |
ES2612922T3 (es) * | 2009-03-11 | 2017-05-19 | Promedior Inc. | Métodos de tratamiento y diagnóstico para trastornos de hipersensibilidad |
PT2405929T (pt) * | 2009-03-11 | 2018-07-23 | Promedior Inc | Métodos de tratamento para distúrbios autoimunes |
WO2010115032A1 (fr) | 2009-04-01 | 2010-10-07 | Promedior, Inc. | Administration pulmonaire et nasale d'une substance amyloïde p sérique |
UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
EP2987803B1 (fr) * | 2009-06-17 | 2018-08-29 | Promedior Inc. | Variantes de sap et leurs utilisations |
-
2010
- 2010-06-17 EP EP15181052.0A patent/EP2987803B1/fr active Active
- 2010-06-17 CA CA2765394A patent/CA2765394C/fr active Active
- 2010-06-17 DK DK15181052.0T patent/DK2987803T3/en active
- 2010-06-17 US US12/817,535 patent/US8329659B2/en active Active
- 2010-06-17 ES ES15181052T patent/ES2708823T3/es active Active
- 2010-06-17 ES ES10790213.2T patent/ES2552793T3/es active Active
- 2010-06-17 DK DK10790213.2T patent/DK2443144T3/en active
- 2010-06-17 EP EP10790213.2A patent/EP2443144B1/fr active Active
- 2010-06-17 AU AU2010262847A patent/AU2010262847B2/en active Active
- 2010-06-17 HU HUE15181052A patent/HUE041034T2/hu unknown
- 2010-06-17 HU HUE10790213A patent/HUE028067T2/en unknown
- 2010-06-17 WO PCT/US2010/039043 patent/WO2010148234A1/fr active Application Filing
- 2010-06-17 PL PL15181052T patent/PL2987803T3/pl unknown
- 2010-06-17 JP JP2012516311A patent/JP5822826B2/ja active Active
- 2010-06-17 CA CA3083911A patent/CA3083911C/fr active Active
-
2012
- 2012-10-12 HK HK12110136.0A patent/HK1169997A1/zh unknown
- 2012-11-06 US US13/669,937 patent/US9556246B2/en active Active
-
2015
- 2015-04-27 JP JP2015090887A patent/JP6124943B2/ja active Active
-
2016
- 2016-08-15 HK HK16109724.6A patent/HK1221478A1/zh unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108114001B (zh) * | 2017-12-23 | 2023-05-30 | 中国科学院海洋研究所 | 一种诱导海产双壳贝类产卵的诱导剂及其应用方法 |
Also Published As
Publication number | Publication date |
---|---|
US8329659B2 (en) | 2012-12-11 |
HK1221478A1 (zh) | 2017-06-02 |
EP2443144B1 (fr) | 2015-08-19 |
US20100323970A1 (en) | 2010-12-23 |
AU2010262847A1 (en) | 2012-01-19 |
CA2765394C (fr) | 2020-08-18 |
DK2443144T3 (en) | 2015-11-23 |
HUE028067T2 (en) | 2016-11-28 |
JP2012530714A (ja) | 2012-12-06 |
ES2708823T3 (es) | 2019-04-11 |
AU2010262847B2 (en) | 2016-06-02 |
HK1169997A1 (zh) | 2013-02-15 |
CA3083911A1 (fr) | 2010-12-23 |
EP2443144A4 (fr) | 2012-11-28 |
DK2987803T3 (en) | 2018-12-17 |
HUE041034T2 (hu) | 2019-05-28 |
US9556246B2 (en) | 2017-01-31 |
CA3083911C (fr) | 2022-11-29 |
WO2010148234A1 (fr) | 2010-12-23 |
JP2015134824A (ja) | 2015-07-27 |
PL2987803T3 (pl) | 2019-04-30 |
EP2443144A1 (fr) | 2012-04-25 |
JP6124943B2 (ja) | 2017-05-10 |
ES2552793T3 (es) | 2015-12-02 |
JP5822826B2 (ja) | 2015-11-24 |
US20130065838A1 (en) | 2013-03-14 |
EP2987803A1 (fr) | 2016-02-24 |
EP2987803B1 (fr) | 2018-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3083911C (fr) | Variants de la sap et leur utilisation | |
JP2012530714A5 (fr) | ||
US10898545B2 (en) | Tear lipocalin muteins binding IL-4 r alpha | |
KR20100017942A (ko) | 독소 펩티드 치료제 | |
KR20160064192A (ko) | 프로톡신-ii 변이체 및 사용 방법 | |
JP2020191860A (ja) | Il−37バリアント | |
JP2013515474A (ja) | 組換え体h因子ならびにそのバリアントおよびコンジュゲート | |
JP2004500100A (ja) | 新規化合物 | |
KR101293805B1 (ko) | 돌연변이된 뉴블라스틴의 중합체 컨주게이트 | |
US7208473B2 (en) | Nucleic acids and protein variants of hG-CSF with granulopoietic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20150610 |